These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23769435)

  • 1. [Mutation-specific antibodies for detection of epidermal growth factor receptor mutations in patients with lung adenocarcinoma].
    Zhang Q; Zhang J
    Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):168-72. PubMed ID: 23769435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunohistochemistry using epidermal growth factor receptor mutation-specific antibodies of delE746-A750 and L858R in lung adenocarcinomas].
    Fan XS; Liu B; Yu B; Shi SS; Wang X; Zhang J; Wang JD; Lu ZF; Ma HH; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):173-7. PubMed ID: 23769436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
    Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
    J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
    Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
    Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
    Wu SG; Chang YL; Lin JW; Wu CT; Chen HY; Tsai MF; Lee YC; Yu CJ; Shih JY
    PLoS One; 2011; 6(8):e23303. PubMed ID: 21858063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of epidermal growth factor receptor mutation specific antibodies in lung adenocarcinoma: evaluation of sensitivity, specificity and relationship to histologic subtypes].
    Lai YM; Feng Q; Sun Y; Wang P; Shi YF; Zhao M; Wu Q; Li XH
    Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):606-11. PubMed ID: 27646888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
    Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
    J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma.
    Ping W; Xia C; Fu S; Cai Y; Deng Y; Sun W; Dong C; Fu X
    Tumour Biol; 2015 Feb; 36(2):693-700. PubMed ID: 25286755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma.
    Ohnishi H; Ohtsuka K; Ooide A; Matsushima S; Goya T; Watanabe T
    Diagn Mol Pathol; 2006 Jun; 15(2):101-8. PubMed ID: 16778591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
    Kozu Y; Tsuta K; Kohno T; Sekine I; Yoshida A; Watanabe S; Tamura T; Yokota J; Suzuki K; Asamura H; Furuta K; Tsuda H
    Lung Cancer; 2011 Jul; 73(1):45-50. PubMed ID: 21129809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor Gene Mutation Detection in Histology and Cytology Specimens of Primary Lung Adenocarcinoma: Immunohistochemistry Versus the Molecular Method.
    Abdul Hamid NS; Mat Zin AA
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1935-1942. PubMed ID: 34181354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
    Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
    J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
    Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
    Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.
    Brevet M; Arcila M; Ladanyi M
    J Mol Diagn; 2010 Mar; 12(2):169-76. PubMed ID: 20093391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma.
    Allo G; Bandarchi B; Yanagawa N; Wang A; Shih W; Xu J; Dalby M; Nitta H; To C; Liu N; Sykes J; Tsao MS
    Histopathology; 2014 May; 64(6):826-39. PubMed ID: 24251405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods.
    Ho HL; Chang FP; Ma HH; Liao LR; Chuang YT; Chang-Chien YC; Lin KY; Chou TY
    Respirology; 2013 Nov; 18(8):1261-70. PubMed ID: 23796143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies.
    Xiong Y; Bai Y; Leong N; Laughlin TS; Rothberg PG; Xu H; Nong L; Zhao J; Dong Y; Li T
    Diagn Pathol; 2013 Feb; 8():27. PubMed ID: 23419122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.